GlassScriptPhysician profile
Thomas David Gazda
NPI 1730158189
$714,410.32
in general payments reported to CMS, 2019-2025
24 companies · $54K in 2025
The $54K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136K · 2020: $41K · 2021: $28K · 2022: $131K · 2023: $207K · 2024: $118K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $252K · Travel and Lodging: $54K · Consulting Fee: $46K · Honoraria: $18K · Food and Beverage: $9,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $252,457.38 |
| Travel and Lodging | $53,525.58 |
| Consulting Fee | $45,585.50 |
| Honoraria | $17,613.00 |
| Food and Beverage | $9,590.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $268,832.41 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $187,610.40 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $73,892.22 | 2019-2025 | Uzedy, Austedo |
| Axsome Therapeutics, INC. | $71,584.63 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $58,078.24 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23,815.54 | 2020-2023 | |
| Bioxcel Therapeutics, INC. | $20,504.92 | 2023 | Igalmi |
| Idorsia Pharmaceuticals US INC | $6,345.88 | 2023 | Quviviq |
| Luye Pharma (USA) LTD. | $1,750.00 | 2025 | Erzofri Extended-Release |
| Abbvie INC. | $716.98 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $243.95 | 2021-2023 | Trintellix |
| Allergan, INC. | $234.72 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $156.65 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $151.08 | 2022-2023 | Qelbree |
| Braeburn INC. | $109.74 | 2025 | Brixadi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $101.28 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $86.07 | 2020-2021 | |
| Corium, LLC | $57.94 | 2023 | Azstarys |
| Neurocrine Biosciences, INC. | $36.43 | 2021 | |
| Lundbeck LLC | $30.05 | 2021-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $25.80 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $17.93 | 2022 | |
| Almatica Pharma LLC | $14.49 | 2023 | Loreev Xr |
| Eisai INC. | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gazda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.